Antithyroid drug therapy of Graves’ hyperthyroidism: realistic goals and focus on evidence

References

• Bartalena L, Wiersinga WM, Pinchera A. Graves’ ophthalmopathy: state of the art and perspectives. J. Endocrinol. Invest. 27, 295–301 (2004).
   PubMedGoogle Scholar
• Weetman AP. Cellular immune responses in autoimmune thyroid disease. Clin. Endocrinol. (Oxf.) 61, 405–413 (2004).
   PubMed Web of Science ®Google Scholar
• Pedersen IB, Knudsen N, Perrild H, Ovesen L, Laurberg P. TSH-receptor antibody measurement for differentiation of hyperthyroidism into Graves’ disease and multinodular toxic goitre: a comparison of two competitive binding assays. Clin. Endocrinol. (Oxf.) 55, 381–390 (2001).
   PubMed Web of Science ®Google Scholar
• Ando T, Latif R, Davies TF. Thyrotropin receptor antibodies: new insights into their actions and clinical relevance. Best Pract. Res. Clin. Endocrinol. Metab. 19, 33–52 (2005).
   PubMedGoogle Scholar
• Codaccioni JL, Orgiazzi J, Blanc P, Pugeat M, Roulier R, Carayon P. Lasting remissions in patients treated for Graves’ hyperthyroidism with propranolol alone: a pattern of spontaneous evolution of the disease. J. Clin. Endocrinol. Metab. 67, 656–662 (1988).
   PubMed Web of Science ®Google Scholar
• Hidaka Y, Tamaki H, Iwatani Y, Tada H, Mitsuda N, Amino N. Prediction of post-partum Graves' thyrotoxicosis by measurement of thyroid stimulating antibody in early pregnancy. Clin. Endocrinol. (Oxf.) 41, 15–20 (1994).
   PubMedGoogle Scholar
• Momotani N, Noh J, Ishikawa N, Ito K. Relationship between silent thyroiditis and recurrent Graves’ disease in the postpartum period. J. Clin. Endocrinol. Metab. 79, 285–289 (1994).
   PubMedGoogle Scholar
• Cooper DS. Antithyroid drugs. N. Engl. J. Med. 352, 905–917 (2005).
   PubMed Web of Science ®Google Scholar
• McCruden DC, Hilditch TE, Connell JM, McLellan AR, Robertson J, Alexander WD. Duration of antithyroid action of methimazole estimated with an intravenous perchlorate discharge test. Clin. Endocrinol. (Oxf.) 26, 33–39 (1987).
   PubMed Web of Science ®Google Scholar
• Okamura K, Ikenoue H, Shiroozu A, Sato K, Yoshinari M, Fujishima M. Reevaluation of the effects of methylmercaptoimidazole and propylthiouracil in patients with Graves’ hyperthyroidism. J. Clin. Endocrinol. Metab. 65, 719–723 (1987).
   PubMed Web of Science ®Google Scholar
• Arntzenius AB, Elte JW, Frolich M, Haak A. The significance of the initial FT4-index for the management of single daily dose methimazole treatment of hyperthyroidism. Clin. Endocrinol. (Oxf.) 29, 239–247 (1988).
   PubMedGoogle Scholar
• Franklyn JA, Daykin J, Drolc Z, Farmer M, Sheppard MC. Long-term follow-up of treatment of thyrotoxicosis by three different methods. Clin. Endocrinol. (Oxf.) 34, 71–76 (1991).
   PubMedGoogle Scholar
• Metso S, Jaatinen P, Huhtala H, Luukkaala T, Oksala H, Salmi J. Long-term follow-up study of radioiodine treatment of hyperthyroidism. Clin. Endocrinol. (Oxf.) 61, 641–648 (2004).
   PubMed Web of Science ®Google Scholar
• Barakate MS, Agarwal G, Reeve TS, Barraclough B, Robinson B, Delbridge LW. Total thyroidectomy is now the preferred option for the surgical management of Graves’ disease. ANZ J. Surg. 72, 321–324 (2002).
   PubMedGoogle Scholar
• Lal G, Ituarte P, Kebebew E, Siperstein A, Duh QY, Clark OH. Should total thyroidectomy become the preferred procedure for surgical management of Graves’ disease? Thyroid 15, 569–574 (2005).
   PubMed Web of Science ®Google Scholar
• Benker G, Vitti P, Kahaly G et al. Response to methimazole in Graves’ disease. The European Multicenter Study Group. Clin. Endocrinol. (Oxf.) 43, 257–263 (1995).
   PubMed Web of Science ®Google Scholar
• Kallner G, Vitols S, Ljunggren JG . Comparison of standardized initial doses of two antithyroid drugs in the treatment of Graves’ disease. J. Intern. Med. 239, 525–529 (1996).
   PubMed Web of Science ®Google Scholar
• Laurberg P, Torring J, Weeke J. A comparison of the effects of propylthiouracil and methimazol on circulating thyroid hormones and various measures of peripheral thyroid hormone effects in thyrotoxic patients. Acta Endocrinol. (Copenh.) 108, 51–54 (1985).
   PubMedGoogle Scholar
• Torring O, Tallstedt L, Wallin G et al. Graves’ hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine – a prospective, randomized study. The Thyroid Study Group. J. Clin. Endocrinol. Metab. 81, 2986–2993 (1996).
   PubMed Web of Science ®Google Scholar
• Tallstedt L, Lundell G, Torring O et al. Occurrence of ophthalmopathy after treatment for Graves’ hyperthyroidism. The Thyroid Study Group. N. Engl. J. Med. 326, 1733–1738 (1992).
   PubMed Web of Science ®Google Scholar
• Bartalena L, Marcocci C, Bogazzi F et al. Relation between therapy for hyperthyroidism and the course of Graves’ ophthalmopathy. N. Engl. J. Med. 338, 73–78 (1998).
   PubMed Web of Science ®Google Scholar
• Romaldini JH, Bromberg N, Werner RS et al. Comparison of effects of high and low dosage regimens of antithyroid drugs in the management of Graves’ hyperthyroidism. J. Clin. Endocrinol. Metab. 57, 563–570 (1983).
   PubMed Web of Science ®Google Scholar
• Abraham P, Avenell A, Watson WA, Park CM, Bevan JS. Antithyroid drug regimen for treating Graves’ hyperthyroidism. Cochrane Database Syst. Rev. 2, CD003420 (2004).
   Google Scholar
• Wenzel KW, Lente JR. Similar effects of thionamide drugs and perchlorate on thyroid-stimulating immunoglobulins in Graves’ disease: evidence against an immunosuppressive action of thionamide drugs. J. Clin. Endocrinol. Metab. 58, 62–69 (1984).
   PubMedGoogle Scholar
• Volpe R. The immunomodulatory effects of anti-thyroid drugs are mediated via actions on thyroid cells, affecting thyrocyte–immunocyte signalling: a review. Curr. Pharm. Des. 7, 451–460 (2001).
   PubMed Web of Science ®Google Scholar
• Cho BY, Shong MH, Yi KH, Lee HK, Koh CS, Min HK. Evaluation of serum basal thyrotrophin levels and thyrotrophin receptor antibody activities as prognostic markers for discontinuation of antithyroid drug treatment in patients with Graves’ disease. Clin. Endocrinol. (Oxf.) 36, 585–590 (1992).
   PubMedGoogle Scholar
• Laurberg P. Mechanisms governing the relative proportions of thyroxine and 3, 5, 3′-triiodothyronine in thyroid secretion. Metabolism 33, 379–392 (1984).
   PubMedGoogle Scholar
• Burmeister LA, Goumaz MO, Mariash CN, Oppenheimer JH. Levothyroxine dose requirements for thyrotropin suppression in the treatment of differentiated thyroid cancer. J. Clin. Endocrinol. Metab. 75, 344–350 (1992).
   PubMedGoogle Scholar
• Izumi Y, Hidaka Y, Tada H et al. Simple and practical parameters for differentiation between destruction-induced thyrotoxicosis and Graves’ thyrotoxicosis. Clin. Endocrinol. (Oxf.) 57, 51–58 (2002).
   PubMed Web of Science ®Google Scholar
• Takamatsu J, Kuma K, Mozai T. Serum triiodothyronine to thyroxine ratio: a newly recognized predictor of the outcome of hyperthyroidism due to Graves’ disease. J. Clin. Endocrinol. Metab. 62, 980–983 (1986).
   PubMedGoogle Scholar
• Prummel MF, Brokken LJ, Wiersinga WM. Ultra short-loop feedback control of thyrotropin secretion. Thyroid 14, 825–829 (2004).
   PubMed Web of Science ®Google Scholar
• Christensen LK, Skovsted L, Hansen JM. Protein-bound iodine during antithyroid treatment. Acta Med. Scand. 185, 483–487 (1969).
   PubMedGoogle Scholar
• Wenzel KW, Lente JR. Syndrome of persisting thyroid stimulation immunoglobulins and growth promotion of goiter combined with low thyroxine and high triiodothyronine serum levels in drug treated Graves’ disease. J. Endocrinol. Invest. 6, 389–394 (1983).
   PubMedGoogle Scholar
• Hegedus L, Hansen JM, Bech K et al. Thyroid stimulation immunoglobulins in Graves’ disease with goiter growth, low thyroxine and increasing triidothyronine during PTU treatment. Acta Endocrinol. (Copenh.) 107, 482–488 (1984).
   PubMedGoogle Scholar
• Takamatsu J, Sugawara M, Kuma K et al. Ratio of serum triiodothyronine to thyroxine and the prognosis of triiodothyronine-predominant Graves’ disease. Ann. Intern. Med. 100, 372–375 (1984).
   PubMedGoogle Scholar
• Chen JJ, Ladenson PW. Discordant hypothyroxinemia and hypertriiodothyroninemia in treated patients with hyperthyroid Graves’ disease. J. Clin. Endocrinol. Metab. 63, 102–106 (1986).
   PubMedGoogle Scholar
• Weetman AP, Shepherdley CA, Mansell P, Ubhi CS, Visser TJ. Thyroid over-expression of type 1 and type 2 deiodonase may account for the syndrome of low thyroxine and increasing triiodothyronine during propylthiouracil treatment. Eur. J. Endocrinol. 149, 443–447 (2003).
   PubMedGoogle Scholar
• Panzer C, Beazley R, Braverman L. Rapid preoperative preparation for severe hyperthyroid Graves’ disease. J. Clin. Endocrinol. Metab. 89, 2142–2144 (2004).
   PubMed Web of Science ®Google Scholar
• Ljunggren JG, Torring O, Wallin G et al. Quality of life aspects and costs in treatment of Graves’ hyperthyroidism with antithyroid drugs, surgery, or radioiodine: results from a prospective, randomized study. Thyroid 8, 653–659 (1998).
   PubMedGoogle Scholar
• Palit TK, Miller CC III, Miltenburg DM. The efficacy of thyroidectomy for Graves’ disease: a meta-analysis. J. Surg. Res. 90, 161–165 (2000).
   PubMedGoogle Scholar
• Alexander EK, Larsen PR. High dose of (131)I therapy for the treatment of hyperthyroidism caused by Graves’ disease. J. Clin. Endocrinol. Metab. 87, 1073–1077 (2002).
   PubMed Web of Science ®Google Scholar
• Cooper DS. The side effects of antithyroid drugs. Endocrinologist 9, 457–476 (1999).
   Web of Science ®Google Scholar
• Vanek C, Samuels MH. Central nervous system vasculitis caused by propylthiouracil therapy: a case report and literature review. Thyroid 15, 80–84 (2005).
   PubMedGoogle Scholar
• Slot MC, Links TP, Stegeman CA, Tervaert JW. Occurrence of antineutrophil cytoplasmic antibodies and associated vasculitis in patients with hyperthyroidism treated with antithyroid drugs: a long-term followup study. Arthritis Rheum. 53, 108–113 (2005).
   PubMed Web of Science ®Google Scholar
• Laurberg P, Buchholtz Hansen PE, Iverson E et al. Goitre size and outcome of medical treatment of Graves’ disease. Acta Endocrinol. (Copenh.) 111, 39–43 (1986).
   PubMedGoogle Scholar
• Laurberg P, Nygaard B, Glinoer D, Grussendorf M, Orgiazzi J. Guidelines for TSH-receptor antibody measurements in pregnancy: results of an evidence-based symposium organized by the European Thyroid Association. Eur. J. Endocrinol. 139, 584–586 (1998).
   PubMed Web of Science ®Google Scholar
• Mandel SJ, Brent GA, Larsen PR. Review of antithyroid drug use during pregnancy and report of a case of aplasia cutis. Thyroid 4, 129–133 (1994).
   PubMed Web of Science ®Google Scholar
• Foulds N, Walpole I, Elmslie F, Mansour S. Carbimazole embryopathy: an emerging phenotype. Am. J. Med. Genet. A. 132, 130–135 (2005).
   Google Scholar
• Momotani N, Yamashita R, Makino F, Noh JY, Ishikawa N, Ito K. Thyroid function in wholly breast-feeding infants whose mothers take high doses of propylthiouracil. Clin. Endocrinol. (Oxf.) 53, 177–181 (2000).
   PubMed Web of Science ®Google Scholar
• Azizi F, Hedayati M. Thyroid function in breast-fed infants whose mothers take high doses of methimazole. J. Endocrinol. Invest. 25, 493–496 (2002).
   PubMed Web of Science ®Google Scholar
• Vestergaard H, Laurberg P. Radioiodine and aggravation of Graves’ ophthalmopathy. Lancet 2(8653), 47 (1989).
   Google Scholar
• Perros P, Kendall-Taylor P, Neoh C, Frewin S, Dickinson J. A prospective study of the effects of radioiodine therapy for hyperthyroidism in patients with minimally active Graves’ ophthalmopathy. J. Clin. Endocrinol. Metab. 90, 5321–5323 (2005).
   PubMed Web of Science ®Google Scholar
• Polak M, Le Gac I, Vuillard E. Fetal and neonatal thyroid function in relation to maternal Graves' disease. Best Pract. Res. Clin. Endocrinol. Metab. 18, 289–302 (2004).
   PubMed Web of Science ®Google Scholar
• Chi SY, Hsei KC, Sheen-Chen SM, Chou FF. A prospective randomized comparison of bilateral subtotal thyroidectomy versus unilateral total and contralateral subtotal thyroidectomy for Graves’ disease. World J. Surg. 29, 160–163 (2005).
   PubMedGoogle Scholar
• Dralle H, Sekulla C. Morbidity after subtotal and total thyroidectomy in patients with Graves’ disease: the basis for decision-making regarding surgical indication and extent of resection. Z. Arztl. Fortbild. Qualitatssich. 98(Suppl. 5), 45–53 (2004).
   PubMedGoogle Scholar
• Takamura Y, Nakano K, Uruno T et al. Changes in serum TSH receptor antibody (TRAb) values in patients with Graves’ disease after total or subtotal thyroidectomy. Endocr. J. 50, 595–601 (2003).
   PubMedGoogle Scholar
• Shizume K. Long term antithyroid drug therapy for intractable cases of Graves’ disease. Endocrinol. Jpn 25, 377–379 (1978).
   PubMedGoogle Scholar
• Slingerland DW, Burrows BA. Long-term antithyroid treatment in hyperthyroidism. JAMA 242, 2408–2410 (1979).
   PubMed Web of Science ®Google Scholar
• Lippe BM, Landaw EM, Kaplan SA. Hyperthyroidism in children treated with long term medical therapy: twenty-five percent remission every two years. J. Clin. Endocrinol. Metab. 64, 1241–1245 (1987).
   PubMed Web of Science ®Google Scholar
• Azizi F, Ataie L, Hedayati M, Mehrabi Y, Sheikholeslami F. Effect of long-term continuous methimazole treatment of hyperthyroidism: comparison with radioiodine. Eur. J. Endocrinol. 152, 695–701 (2005).
   PubMed Web of Science ®Google Scholar
• Nedrebo BG, Holm PI, Uhlving S et al. Predictors of outcome and comparison of different drug regimens for the prevention of relapse in patients with Graves’ disease. Eur. J. Endocrinol. 147, 583–589 (2002).
   PubMed Web of Science ®Google Scholar
• Glinoer D, de Nayer P, Bex M. Effects of l-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves’ hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study. Eur. J. Endocrinol. 144, 475–483 (2001).
   PubMed Web of Science ®Google Scholar
• Alexander WD, Harden RM, Koutras DA, Wayne E. Influence of iodine intake after treatment with antithyroid drugs. Lancet 2(7418), 866–868 (1965).
   PubMedGoogle Scholar
• Roti E, Gardini E, Minelli R. Effects of chronic iodine administration on thyroid status in euthyroid subjects previously treated with antithyroid drugs for Graves’ hyperthyroidism. J. Clin. Endocrinol. Metab. 76, 928–932 (1993).
   PubMedGoogle Scholar
• Braverman LE. Iodine and the thyroid: 33 years of study. Thyroid 4, 351–356 (1994).
   PubMedGoogle Scholar
• Preissner CM, Wolhuter PJ, Sistrunk JW, Homburger HA, Morris JC III. Comparison of thyrotropin-receptor antibodies measured by four commercially available methods with a bioassay that uses Fisher rat thyroid cells. Clin. Chem. 49, 1402–1404 (2003).
   PubMedGoogle Scholar